LENZ Therapeutics Stock Forecast

Stock Price Forecast

According to 6 analysts polled by S&P Global, LENZ Therapeutics stock has a consensus rating of "Buy" and an average price target of $14.83. The average 1-year stock price forecast is 245.69% higher than the current stock price, while the lowest is $4.00 (-6.76%) and the highest is $45 (+948.95%).

Price Target: $14.83 (+245.69%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$4.00	$14.83	$9.50	$45
Change	-6.76%	+245.69%	+121.45%	+948.95%

Analyst Ratings

The average analyst rating for LENZ Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Oct '26	Nov '26
Strong Buy	6	6	6	5	4	4
Buy	0	0	0	0	0	0
Hold	1	1	1	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yigal Nochomovitz Citi	Citi	Buy Maintains $10 → $9	Buy	Maintains	$10 → $9	+109.79%	Nov 5, 2026
Jason Gerberry Bank of America Securities	Bank of America Securities	Hold Reiterates $7 → $4	Hold	Reiterates	$7 → $4	-6.76%	Oct 30, 2026
Matthew Caufield H.C. Wainwright	H.C. Wainwright	Buy Reiterates $38 → $16	Buy	Reiterates	$38 → $16	+272.96%	Oct 30, 2026
Stacy Ku TD Cowen	TD Cowen	Buy Maintains $50 → $45	Buy	Maintains	$50 → $45	+948.95%	Oct 29, 2026
Biren Amin Piper Sandler	Piper Sandler	Hold Maintains $7 → $5	Hold	Maintains	$7 → $5	+16.55%	Oct 19, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

14.47M

from 19.09M

-24.20%

from 19.09M

Revenue Next Year

32.63M

from 14.47M

125.50%

from 14.47M

EPS This Year

-4.08

from -2.85

EPS Next Year

-1.47

from -4.08

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	15.00M	-	-	19.09M	14.47M
Revenue Growth	-	-	-	-	-	-24.20%
Gross Profit	-	15.00M	-	-	18.67M	12.01M
Gross Margin	-	100.00%	-	-	97.81%	83.00%
Operating Income	-6.69M	-10.48M	-72.43M	-58.61M	-91.14M	-132.15M
Net Income	-7.56M	-10.81M	-69.97M	-49.77M	-82.13M	-130.33M
EPS	-	-	-	-	-2.85	-4.08
Free Cash Flow	-	-	-	-	-70.00M	-146.90M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	15.0M
Avg	14.5M
Low	14.1M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-21.4%
Avg	-24.2%
Low	-26.1%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-3.81
Avg	-4.08
Low	-4.18

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-